FOLH1 and neoplasm: Furthermore, as PC lacks responsiveness to immunotherapy due to its immunosuppressive tumor microenvironment 30 and low tumor mutational burden 31, it could be explored whether the combination of EBRT and PSMA-RLT might stimulate the host immunity to the tumor and improve the efficacy of immunotherapy.